These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 16670731)

  • 1. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.
    Murillo O; Arina A; Tirapu I; Alfaro C; Mazzolini G; Palencia B; López-Diaz De Cerio A; Prieto J; Bendandi M; Melero I
    Clin Cancer Res; 2003 Nov; 9(15):5454-64. PubMed ID: 14654524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic potential of 4-1BB (CD137) in cancer.
    Nam KO; Kang WJ; Kwon BS; Kim SJ; Lee HW
    Curr Cancer Drug Targets; 2005 Aug; 5(5):357-63. PubMed ID: 16101383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccination with tumor cells that engage CD137.
    Hellstrom KE; Hellstrom I
    J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with agonistic anti-CD137: two sides of a coin.
    Sun Y; Chen JH; Fu Y
    Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.
    Zhang H; Knutson KL; Hellstrom KE; Disis ML; Hellstrom I
    Mol Cancer Ther; 2006 Jan; 5(1):149-55. PubMed ID: 16432173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice.
    Sabel MS; Conway TF; Chen FA; Bankert RB
    J Immunother; 2000; 23(3):362-8. PubMed ID: 10838665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
    Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
    Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
    Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
    Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
    Kocak E; Lute K; Chang X; May KF; Exten KR; Zhang H; Abdessalam SF; Lehman AM; Jarjoura D; Zheng P; Liu Y
    Cancer Res; 2006 Jul; 66(14):7276-84. PubMed ID: 16849577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling.
    Sun Y; Blink SE; Chen JH; Fu YX
    J Immunol; 2005 Jul; 175(2):884-90. PubMed ID: 16002686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
    Sanmamed MF; Pastor F; Rodriguez A; Perez-Gracia JL; Rodriguez-Ruiz ME; Jure-Kunkel M; Melero I
    Semin Oncol; 2015 Aug; 42(4):640-55. PubMed ID: 26320067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro.
    Zhang L; Wang Q; Wang X; Ding P; Song J; Ma C; Sun W
    Cell Mol Immunol; 2004 Feb; 1(1):71-6. PubMed ID: 16212924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
    Wilcox RA; Flies DB; Zhu G; Johnson AJ; Tamada K; Chapoval AI; Strome SE; Pease LR; Chen L
    J Clin Invest; 2002 Mar; 109(5):651-9. PubMed ID: 11877473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis.
    Sun Y; Lin X; Chen HM; Wu Q; Subudhi SK; Chen L; Fu YX
    J Immunol; 2002 Feb; 168(3):1457-65. PubMed ID: 11801689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model.
    Sytwu HK; Lin WD; Roffler SR; Hung JT; Sung HS; Wang CH; Cheng TL; Tsou SC; Hsi SC; Shen KL
    J Autoimmun; 2003 Nov; 21(3):247-54. PubMed ID: 14599849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
    Dempke WCM; Fenchel K; Uciechowski P; Dale SP
    Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
    Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
    J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice.
    Foell J; McCausland M; Burch J; Corriazzi N; Yan XJ; Suwyn C; O'Neil SP; Hoffmann MK; Mittler RS
    Ann N Y Acad Sci; 2003 Apr; 987():230-5. PubMed ID: 12727643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.